Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Short term Debt (2016 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Short term Debt for 8 consecutive years, with $28.3 million as the latest value for Q4 2023.

  • For Q4 2023, Short term Debt changed N/A year-over-year to $28.3 million; the TTM value through Dec 2023 reached $28.3 million, changed N/A, while the annual FY2023 figure was $28.3 million, N/A changed from the prior year.
  • Short term Debt hit $28.3 million in Q4 2023 for Cartesian Therapeutics, up from $10.2 million in the prior quarter.
  • Across five years, Short term Debt topped out at $28.3 million in Q4 2023 and bottomed at $460000.0 in Q1 2021.
  • Average Short term Debt over 5 years is $11.2 million, with a median of $9.3 million recorded in 2020.
  • Year-over-year, Short term Debt crashed 97.27% in 2021 and then surged 1368.1% in 2023.
  • Cartesian Therapeutics' Short term Debt stood at $18.9 million in 2019, then tumbled by 55.65% to $8.4 million in 2020, then dropped by 28.9% to $6.0 million in 2021, then decreased by 1.38% to $5.9 million in 2022, then skyrocketed by 381.49% to $28.3 million in 2023.
  • According to Business Quant data, Short term Debt over the past three periods came in at $28.3 million, $10.2 million, and $10.2 million for Q4 2023, Q2 2023, and Q1 2023 respectively.